

HepLOGIC

Pilot and feasibility study



Interested in data-driven healthcare improvement?

HepLOGIC is a digital clinical decision-support system that aims to reduce the incidence of preventable liver cancer caused by chronic viral hepatitis. HepLOGIC uses the POLAR business intelligence tool, which integrates with practice software and electronic medical records, to prompt screening of people at risk of hepatitis B and hepatitis C infection and support the clinical care of those diagnosed.

We are looking for 20 general practices to help us test HepLOGIC in a pilot and feasibility study.

Participation will require you to:

- Enter into a participation agreement with the Royal Melbourne Hospital.
- Implement HepLOGIC in your practice.
- Allow relevant practice staff to undertake HepLOGIC training (30 minutes) and participate in short evaluation surveys at two points in the study (30 minutes each).
- Nominate a staff member (practice manager, nurse or GP) as a liaison point for the study and to facilitate uptake and evaluation of HepLOGIC (1-4 hours per month depending on study phase).

The study will run for 14 months, with implementation of HepLOGIC scheduled for April 2023 and final evaluation data being collected in May 2024.

Your practice can be involved if it:

- Is in the Gippsland, Eastern Melbourne or South Eastern Melbourne Primary Health Network regions.
- Has at least 1,800 RACGP-active patient records.
- Participates in the POLAR data sharing research program.
- Uses Best Practice or Medical Director (Clinical) software.

Contact your Primary Health Network for more information about POLAR, the project, or to express interest in participating.

Why be involved?

Liver cancer is one of the leading causes of cancer death in Australia. Most cases are preventable, with the majority caused by chronic hepatitis B and hepatitis C infection. However, many people living with these conditions are undiagnosed, as risk factors for testing are broad and people are generally asymptomatic until adverse outcomes occur.

The benefits of involvement are:

- Easier identification of patients at risk of chronic viral hepatitis and liver cancer and integrated support to assist in the management of their health.
- Direct access to viral hepatitis specialist advice.
- Tailored monthly practice performance reports against viral hepatitis and liver cancer measures.
- Tools to support data collection for ethnicity and Aboriginal and Torres Strait Islander status.
- Support for PIP QI continuous quality improvement activities and incentive payments.
- \$5,000 practice payment.

About us

This project is led by the Royal Melbourne Hospital at the Doherty Institute, with the support of Gippsland, Eastern Melbourne and South Eastern Melbourne Primary Health Networks, and Outcome Health.

HepLOGIC is funded by the Victorian Government, through the Victorian Cancer Agency.

For more information visit:

<https://www.doherty.edu.au/whoccvh/heplogicstudy>

Or contact your Primary Health Network:

Gippsland research@gphn.org.au

Eastern Melbourne digitalhealth@emphn.org.au

South Eastern Melbourne digitalhealth@semphn.org.au